TNDM
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, P/B 9.35, Graham Number None
- P/S ratio of 1.43 is relatively modest for med-tech
- Price/Book of 9.35 is excessively high
- No positive P/E or Graham Number available due to losses
Ref Revenue Growth 2.70%, EPS Growth +97.7%
- EPS is trending upward (reducing losses)
- Strong analyst price targets
- Revenue growth is nearly flat at 2.70%
- Forward P/E remains deeply negative
Ref 5Y Change -77.5%
- Recent 6-month recovery (+36.7%)
- Catastrophic 5-year return (-77.5%)
- Consistent history of earnings misses in 2022-2023
Ref Piotroski F-Score 1/9, Debt/Equity 2.90
- Current Ratio > 2.0
- Piotroski F-Score 1/9 (Weak)
- Debt/Equity 2.90
- ROE -97.89%
Ref Yield N/A
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TNDM and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care, Inc.
Primary
|
-77.5% | -43.3% | +29.6% | +36.7% | -14.4% | +5.7% |
|
GLUE
Monte Rosa Therapeutics, Inc.
Peer
|
-14.8% | +121.2% | +344.6% | +113.4% | +4.5% | +5.6% |
|
AVAH
Aveanna Healthcare Holdings Inc.
Peer
|
-42.4% | +506.1% | +26.3% | -14.5% | -9.6% | -1.7% |
|
PGNY
Progyny, Inc.
Peer
|
-63.7% | -45.0% | -16.2% | -15.9% | -0.7% | +8.5% |
|
GENB
Generate Biomedicines, Inc.
Peer
|
-8.8% | -8.8% | -8.8% | -8.8% | -5.6% | -16.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care, Inc.
|
BEARISH | $1.46B | - | -97.9% | -20.2% | $21.24 | |
|
GLUE
Monte Rosa Therapeutics, Inc.
|
NEUTRAL | $1.44B | - | -16.9% | -31.2% | $18.05 | Compare |
|
AVAH
Aveanna Healthcare Holdings Inc.
|
BEARISH | $1.44B | 18.68 | -% | 3.3% | $6.91 | Compare |
|
PGNY
Progyny, Inc.
|
BULLISH | $1.47B | 26.76 | 12.5% | 4.5% | $17.93 | Compare |
|
GENB
Generate Biomedicines, Inc.
|
BEARISH | $1.47B | - | -81.7% | -% | $11.53 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-15 | KYRILLOS JEAN-CLAUDE | Chief Operating Officer | Stock Award | 3,636 | - |
| 2026-03-17 | NOVARA MARK DAVID | Officer | Sale | 187 | $4,310 |
| 2026-03-16 | NOVARA MARK DAVID | Officer | Stock Award | 7,414 | - |
| 2026-03-05 | NOVARA MARK DAVID | Officer | Sale | 2 | $46 |
| 2026-02-17 | CARPENTER RICK | Chief Technology Officer | Stock Award | 2,334 | - |
| 2026-02-17 | SHERIDAN JOHN F | Chief Executive Officer | Stock Award | 11,454 | - |
| 2026-02-17 | MORRISON SUSAN M | Officer | Stock Award | 2,600 | - |
| 2026-02-17 | VOSSELLER LEIGH A | Chief Financial Officer | Stock Award | 2,998 | - |
| 2026-02-17 | GASSER ELIZABETH ANNE | Officer | Stock Award | 2,600 | - |
| 2026-02-17 | HANSEN SHANNON MARIE | Officer | Stock Award | 3,065 | - |
| 2026-02-17 | NOVARA MARK DAVID | Officer | Stock Award | 77 | - |
| 2026-01-15 | KYRILLOS JEAN-CLAUDE | Chief Operating Officer | Stock Award | 3,636 | - |
| 2025-12-15 | CARPENTER RICK | Chief Technology Officer | Stock Award | 406 | - |
| 2025-12-15 | NOVARA MARK DAVID | Officer | Stock Award | 7,415 | - |
| 2025-11-17 | CARPENTER RICK | Chief Technology Officer | Stock Award | 339 | $5,285 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Tandem Diabetes Care (TNDM) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. While specific financial metrics were not provided in the excerpts, the filing includes comprehensive disclosures on risk factors, liquidity, and results of operations. Management cautions that forward-looking statements regarding the company's future financial condition are subject to considerable risks and uncertainties.
Tandem Diabetes Care (TNDM) filed its quarterly 10-Q report on November 6, 2025, which includes disclosures regarding company risk factors and the unregistered sale of equity securities. While specific financial metrics were not provided in the excerpt, the filing highlights recent capital activity through the issuance of equity.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning TNDM from our newsroom.